Updated:
Alexandria Real Estate Equities
Joel S. Marcus launched Alexandria Real Estate Equities in 1994 after his prior role as a venture capital lawyer, recognizing early that biotechnology...
Alexandria Real Estate Equities
Joel S. Marcus launched Alexandria Real Estate Equities in 1994 after his prior role as a venture capital lawyer, recognizing early that biotechnology firms needed specialized, capital-intensive lab space that traditional office landlords would not provide. The company, structured as a public REIT, pioneered the concept of the 'collaborative life science cluster' — large, contiguous campuses that cluster academic medical centers, Big Pharma outposts, and venture-backed startups within walking distance of each other. Alexandria went public on the New York Stock Exchange in 1997 and has since grown into the only pure-play life science REIT of its scale in the United States. The firm acquired the 14-building MIT Technology Square in Cambridge in 2000, a deal that anchored its long-term dominance in the Kendall Square submarket (per public records, 2000). Alexandria's deployment strategy concentrates on ground-up development and strategic acquisitions of Class A laboratory and office space in five metropolitan clusters: Greater Boston, the San Francisco Bay Area, San Diego, Seattle, and the New York City metro region. Over 80 percent of its annual gross investment volume targets pre-leased or partially pre-leased development projects rather than speculative construction. The tenant roster spans multinational corporations like Novartis and Eli Lilly, as well as pre-IPO biotechs including Moderna — which Alexandria housed in Cambridge before and during the company's COVID vaccine scale-up. The firm also operates an in-house venture capital arm, Alexandria Venture Investments, which makes strategic minority investments in early-stage tenants to deepen the ecosystem relationship. The company operates as a vertically integrated entity, with in-house architecture, development, asset management, and leasing teams across its key markets. As of early 2025, Alexandria's market capitalization exceeds $20 billion, ranking it among the largest non-residential REITs globally by equity value. Peter M. Moglia, a more than two-decade veteran of the firm, now serves as CEO and Chief Investment Officer alongside Marcus's continuing Executive Chairman role. Recent activity includes the November 2024 grand opening of the One Alexandria Square campus in San Diego's Torrey Pines submarket, designed as a shared hub integrating Alexandria's own operating company with its life science tenant ecosystem. Alexandria's structural differentiator lies in its quasi-sovereign role within the biotech capital stack — it is not merely a passive landlord but an active zone-builder that shapes municipal zoning, partners with governments on infrastructure upgrades, and seeds its own future tenants through the venture arm. This creates a feedback loop where the real estate portfolio's occupancy demand is partially self-generated, insulating the business from sector-wide leasing downturns in a way that conventional office REITs cannot replicate.
General information
Firm type
Asset Manager
Year founded
1994
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Pasadena
Corporate office
Pasadena, CA, United States
Principals
Joel S. Marcus
Executive Chairman and Founder
Peter M. Moglia
Chief Executive Officer and Chief Investment Officer
Sector focus
Frequently asked questions
Who runs day-to-day investment decisions at Alexandria Real Estate Equities?
Peter M. Moglia serves as Chief Executive Officer and Chief Investment Officer, overseeing all capital deployment and asset management. Founder Joel S. Marcus remains Executive Chairman and continues to shape long-term strategic direction. The investment committee integrates the executive team with regional market heads who source and underwrite every acquisition and development deal.
How does Alexandria source its proprietary real estate pipeline?
The firm relies on deep local relationships with university systems, hospital networks, and municipal planning departments in its core markets. Its in-house venture arm, Alexandria Venture Investments, functions as an early intelligence network — the team meets founders years before they need 100,000 square feet, allowing the real estate side to assemble land and entitle sites proactively. Many competitors cannot replicate this origination funnel because they lack the venture capital adjacency.
Is Alexandria purely a landlord, or does it take equity stakes in tenants?
Alexandria operates both as a direct landlord and as a venture capital participant through Alexandria Venture Investments. The venture arm makes early-stage minority equity commitments to life science and technology companies, often before those companies lease space. This dual exposure allows the firm to benefit from both the stable cash flows of laboratory rents and the upside of drug discovery and platform technology breakthroughs.
What investment stages does Alexandria Venture Investments typically target?
Alexandria Venture Investments focuses on seed through growth-stage biotechnology, diagnostics, research tools, and digital health companies. Investments are typically sub-$10 million initial checks and are concentrated in the same knowledge clusters where the REIT owns laboratory campuses. The unit has invested in hundreds of companies since inception, with a focus on capital-efficient therapeutics and platform biology businesses that are likely to need physical lab space.
Which sectors does Alexandria explicitly avoid in its real estate portfolio?
The firm avoids traditional office, retail, industrial, and multifamily residential properties entirely. It does not acquire non-life-science buildings and does not diversify into generic commercial real estate. Even within life science, Alexandria has historically avoided single-tenant lab buildings in tertiary university towns without a dense cluster of research institutions and venture capital activity.
How is Alexandria structured from an equity standpoint, and where can an allocator gain exposure?
Alexandria Real Estate Equities is a publicly traded real estate investment trust listed on the New York Stock Exchange under the ticker ARE. It maintains the standard REIT structure, meaning it distributes at least 90 percent of taxable income to shareholders annually. The company is widely held by institutional REIT-dedicated funds, healthcare-sector equity funds, and major index vehicles, including those tracking the S&P 500.
What is Alexandria's relationship with the biotech firms it houses during a downturn?
Because many tenants are pre-revenue and rely on venture funding, Alexandria's credit underwriting evaluates both traditional balance-sheet metrics and the scientific quality of the tenant's pipeline. The firm has historically maintained occupancy resilience during recessions by offering partial lease restructurings and by deploying its venture arm as a liquidity source for struggling portfolio companies — an option unavailable to conventional office landlords.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: